Page 90 - MEMORIA ANUAL 2019 SEHH-FEHH

MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Ganster C, Ades L, Giovanni Della Porta M, Smith A, Werner Y, Patel MA, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pel- lagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Béjar R, Greenberg PL, Cazzola M, Hellstrom Lindberg E, Ogawa S, Papaemmanuil E. TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood. 2019;134(Supplement_1):675. https://doi. org/10.1182/blood-2019-129392.
– Hernández Mohedo F, Alarcón Payer C, Mora Casterá E, Romero Domínguez S, López Andrade B, González AR, Sanz G. Long-term Benefits After Discontinua- tion Of Lenalidomide Due To Adverse Events In Patients With Del (5q) Myelo- dysplastic Syndromes.
– Hernández Mohedo F, Solé Ristol F, Bernal Sánchez M, Palomo Sanchís L, Jura- do Chacón M. Clinical And Mutational Profiles Differentiate Hypoplastic From Hyperplastic Myelodysplastic Syndrome And Myelodysplastic Syndrome With Isolated Deletion Of 5q.
• 60th ASH Annual Meeting 2019:
– Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso Domínguez JM, Alonso A, Coombs CC, Deeg HJ, Donnellan WB, Foran JM, García-Manero G, Maris MB, Mc- Masters M, Micol JB, Pérez de Oteyza J, Thol F, Wang ES, Watts JM, Buonamici S, Kim A, Gourineni V, Marino AJ, Rioux N, Schindler J, Smith S, Yao H, Yuan X, Yu K, Platzbecker U. Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood. 2019;134(Supple- ment_1):673. https://doi.org/10.1182/blood-2019-123854.
Presentaciones orales en congresos nacionales
• LXI Congreso Nacional de la Sociedad Española de Hematología y Hemotera- pia (SEHH) y XXXV Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia (SETH):
– Zurdo M, Hurtado AM, Chen-Liang TH, Martínez-Banaclocha H, Palomo L, López- Cadenas F, Lumbreras E, Zamora L, Xicoy B, Díez-Campelo M, Solé F, Vicente V,
GRUPO ESPAñOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
90